ER expression	Non Small Cell Lung Cancer	ER expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
ER expression	Endometrial Cancer	ER expression	Endometrial Cancer	Immunotherapy + Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Immunotherapy + Tyrosine kinase inhibitor Sensitive : C3	Immunotherapy + Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Immunotherapy + Tyrosine kinase inhibitor Sensitive : C3
ER expression	Endometrial Cancer	ER expression	Endometrial Cancer	pembrolizumab + lenvatinib Resistant: C3 – Early Trials pembrolizumab + lenvatinib Resistant : C3	pembrolizumab + lenvatinib Resistant: C3 – Early Trials pembrolizumab + lenvatinib Resistant : C3

ER expression

Associations